Sign in
CompletedNo phase

Central Blood Pressure and Variability Evaluation

Key facts

Who runs it
Imperial College Healthcare NHS Trust
Where
United Kingdom2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
137 people enrolled
Started
7 Jun 2022
Ended
30 Jun 2024
Type of study
Observational
Record updated
31 January 2025

Who can take part

Age
55 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Willing and able to give written informed consent
  • infrarenal aneurysms of ≥3cm in size (to include AAA ≥5.5cm in those not proceeding to surgery)

Who cannot take part

  • participation in another trial of an investigational product or device within the previous 30 days
  • persistent cardiac arrhythmia
  • age<55
  • any clinically significant medical condition which, in the opinion of the investigator, may interfere with the study results and/or reduce life expectancy to < 2 years
  • Patient's with a known genetic aetiology of their AAA
  • known bilateral proximal upper extremity obstructive lesions
  • those unable to give informed consent
  • those too frail to travel for four monthly surveillance
  • unable or unwilling to comply with the requirements of the study, in the opinion of the investigator

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Background: A sub-study of the AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK) trial indicated a statistically significant association between central blood pressure (BP) variability and abdominal aortic aneurysm (AAA) growth. The role of anti-hypertensive adherence has not been explored in the context of AAA growth.

Read full original descriptionShow less

Objective: To confirm whether higher central BP variability is associated with higher AAA growth rates and to examine the effect of medication adherence on AAA growth rates in a prospective longitudinal cohort study.

Methods: Up to 175 patients will be recruited over ten months from two sites with standardised quality control of AAA, BP and antihypertensive non-adherence measurement. Patients (>55 years), with AAAs ≥3cm in diameter (including AAA ≥5.5cm, not proceeding to surgery) will be recruited and undergo AAA ultrasound (US), BP (peripheral and central) and antihypertensive non-adherence measurements every four months (+/- one month) for 24 months. Ambulatory BP variability data will be collected. Data on medication adherence and beliefs around medications will be collected with validated questionnaires.

Analysis: Primarily, the relationship between central diastolic BP visit-to-visit variability and AAA growth (estimated by multilevel modelling) based on US measurements and secondarily the relationship between central diastolic BP variability and time taken to reach the threshold for AAA repair (5.5 cm) or rupture.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Investigation Into the Effects of Central Blood Pressure Variability and Antihypertensive Adherence on the Size and Growth Rate of Abdominal Aortic Aneurysms
Record updated
31 January 2025